Trial Profile
Phase I/II Study of Veltuzumab Combined With 90Y-Epratuzumab Tetraxetan in Patients With Relapsed/Refractory, Aggressive Non- Hodgkin's Lymphoma.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Epratuzumab Y-90 (Primary) ; Veltuzumab (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma; Mantle-cell lymphoma
- Focus Adverse reactions
- Sponsors Gilead Sciences; Immunomedics
- 03 Dec 2020 Status changed from active, no longer recruiting to withdrawn prior to enrolment.
- 02 Mar 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
- 11 Jun 2013 The phase II part of this study is now underway, according to an Immunomedics media release.